Evofem receives $106.8M debt acceleration notice; closes $460K private placement with Aditxt

Evofem Biosciences, Inc.

Future Pak LLC (agent) claims Event of Default under SPA; repurchase price ~$106.8M if all Purchasers exercise Section 5.7 Option.
Evofem 'strongly disagrees' with default claim and intends to vigorously contest it.
Closed private placement with Aditxt: 460 shares Series F-1 Preferred for $460,000; registration rights granted.
Third Amendment to Merger Agreement adjusts Aditxt equity investment: 720 shares due Oct 2, 2280 shares due Oct 31.
Merger sub (Adifem) to merge into Evofem; Evofem to become wholly owned subsidiary of Aditxt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.